Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STM11315
- Development stage
- Unknown
- Lead developer
- STORM Therapeutics
- Modality
- Small Molecules
01
Overview
**STM11315** is a small molecule inhibitor targeting DHX9, an RNA helicase involved in RNA processing and implicated in cancer. It demonstrates compelling single-agent anti-tumor activity in preclinical models, achieving complete and durable tumor regression. Developed through discovery efforts likely associated with STORM Therapeutics' RNA-modifying enzyme platform, it represents a novel approach to oncology by modulating RNA biology to inhibit tumor growth.[11]
Beyond the preview
Go deeper on STM11315.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STM11315.